Subscribe

Rheumatoid Arthritis

Improved biologic agents’ efficacy enhances QALYs by Neil Canavan Berlin, Germany—Data presented at the 2012 European League Against Rheu­matism (EULAR) Congress showed that combating rheumatoid arthritis (RA) with an approach that tailors the administration of biologic agents according to the specific needs of the individual patient with RA can reduce the costs dramatically, saving €2,595,557 per 272 patients over a 3-year period, and at the same time increasing treatment efficacy by an average of 3.67 quality-adjusted life-years (QALYs).
By Sy Schlager, MD, PhD The development of biomarkers as tools for the measurement of disease activity to predict disease progression and response to certain therapies and the investigation of new classes of agents for the treatment of rheumatoid arthritis (RA) are 2 major advances in the management of patients with RA.
By Wayne Kuznar More than 25% of patients with rheumatoid arthritis (RA) who are started on methotrexate (Trexall, Rheumatrex) alone achieve clinical remission at week 24, and the remission is durable out to 2 years, said James R. O’Dell, MD, Professor of Internal Medicine, Divi­sion of Rheuma­tology, University of Nebraska Medical Center, Omaha, at the 2011 meeting of the American College of Rheumatology.
The number of total hip replacement (THR) and total knee replacement (TKR) surgeries has declined among patients with a primary diagnosis of rheumatoid arth­ritis (RA) since the introduction of biologic agents.
By Phoebe Starr After achieving low disease activity (LDA) while receiving full-dose induction etanercept (Enbrel) therapy at 36 weeks, patients with moderately active rheumatoid arthritis (RA) can be maintained on half-dose etanercept instead of full-dose etanercept for a further 52 weeks...
By Wayne Kuznar Routine screening for replicating JC polyomavirus (JCPyV) or serum antibodies does not seem to be warranted in rheumatic patients treated with rituximab (Rituxan).
New oral therapies, such as Janus kinase (JAK) inhibitors and spleen tyrosine kinase inhibitors, will be challenged to break the grip on the market held by the leading large-molecule therapies in the treatment of rheumatoid arthritis (RA).
Page 9 of 9
Results 81 - 87 of 87
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology